SPRAVATO®
(esketamine)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SPRAVATO® (esketamine)
Medical Information
Use in Patients with Comorbid Multiple Sclerosis
Last Updated: 03/03/2025
Summary
Comorbid multiple sclerosis was not an exclusion criterion in the SPRAVATO clinical trial programs.
LITERATURE SEARCH
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 26 February 2025 did not identify any relevant citations pertaining to this topic.